GlobalData Healthcare

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood sugar. However, these drugs also act on the brain’s reward system, an area deeply involved in addiction. […]

US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes of Health (NIH), signalling headwinds in securing NIH grant funding for biopharmaceutical research and development (R7D). NIH Small Business Innovation

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) – the US, France, Germany, Italy, Spain, the UK, and Japan – is projected to experience significant growth, with sales increasing from $2.3bn in 2023 to $5.2bn by

Drugs targeting the glucagon-like peptide-1 receptor (GLP-1R) demonstrated remarkable success in 2023, with approved products generating sales of $37.2 billion. Currently, there are 323 active GLP-1Rs in the pipeline, with several estimated to deliver significant returns upon launch. While mega-cap

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications. According to leading data and analytics company GlobalData,

Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that they experience, which include itchiness and skin

Severe asthma is traditionally classified into either high or low T-helper cell type 2 (T2) subtypes. T2-high asthma, which is characterised by allergic inflammation and elevated eosinophil levels, has seen significant advances in treatment and disease management with the advent

Following a challenging two-year downturn, private biopharmaceutical venture financing saw a 20% ($3.8 million) increase in total deal value from 2023 to $22.4 million in 2024 year-to-date (YTD), according to GlobalData’s Pharma Intelligence Center deals database. This growth is an

The Biosecure Act was left out of a key US defence bill that passed in the House this week, in a major win for Chinese CDMOs. Shares in WuXi AppTec (Shanghai, China) opened 10.5% higher on December 9 compared to

Representative image to depict Hemophilia World Day. Image credit: Getty Images/ AndreyPopov At the American Society of Hematology (ASH) Annual Meeting 2024, physicians looked back at the progress made in the prophylactic and curative care of hemophilia since the approval